{
    "data": [
        {
            "id": "4657379",
            "type": "article",
            "attributes": {
                "publishOn": "2023-12-12T02:29:18-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286471429/image_1286471429.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107012",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "508324",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2433",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4657379-baxter-cheap-big-pharma-stock-improving-earnings-plus-3-percent-dividend-yield"
            }
        },
        {
            "id": "4640415",
            "type": "article",
            "attributes": {
                "publishOn": "2023-10-12T10:54:14-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1491876823/image_1491876823.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105843",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "493001",
                            "type": "sentiment"
                        },
                        {
                            "id": "493002",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2433",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4640415-should-you-buy-baxter-davita-after-fallout-from-ozempic-trial"
            }
        },
        {
            "id": "4628309",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-14T16:33:59-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810122/image_1445810122.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Challengers Review: Baxter International",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "52212",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "477855",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2433",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4628309-dividend-challengers-review-baxter-international"
            }
        },
        {
            "id": "4611059",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-12T19:02:01-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396801868/image_1396801868.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "107045",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "462889",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2433",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4611059-baxter-international-hillrom-could-be-a-tailwind-for-fcf"
            }
        },
        {
            "id": "4593492",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-11T14:43:35-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364369624/image_1364369624.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons To Consider A Nibble On Baxter",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105843",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "449217",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2433",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4593492-3-reasons-to-consider-a-nibble-on-baxter"
            }
        },
        {
            "id": "4575221",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-03T17:00:35-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419845852/image_1419845852.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Baxter International: Another YoY Earnings Decline Expected, Shares Tag Support",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "435657",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2433",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4575221-baxter-international-another-yoy-earnings-decline-expected-shares-tag-support"
            }
        },
        {
            "id": "4567285",
            "type": "article",
            "attributes": {
                "publishOn": "2023-01-02T05:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 95,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329767050/image_1329767050.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Baxter Is One Of My #1 2023 Bets For Healthcare/Medtech",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "428842",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "2433",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4567285-baxter-stock-one-of-my-2023-bets-healthcaremedtech"
            }
        }
    ]
}